Clinical Trial Update: A Study of Anti-IL-6R mAb Injection in Patients With iMCD [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating an anti-IL-6 receptor monoclonal antibody in idiopathic multicentric Castleman's disease is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Multicentric Castleman Disease

Drugs mentioned

• Anti-IL-6R monoclonal antibody

Snippet

Sponsor: Beijing VDJBio Co., LTD. | Conditions: Idiopathic Multicentric Castleman's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING